<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35599283</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1559-131X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Medical oncology (Northwood, London, England)</Title>
          <ISOAbbreviation>Med Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.</ArticleTitle>
        <Pagination>
          <StartPage>97</StartPage>
          <MedlinePgn>97</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12032-022-01696-x</ELocationID>
        <Abstract>
          <AbstractText>Myeloproliferative neoplasms (MPN) are hematological disorders characterized by increased proliferation of precursor and mature myeloid cells. MPN patients may present driver mutations in JAK2, MPL, and CALR genes, which are essential to describe the molecular mechanisms of MPN pathogenesis. Despite all the new knowledge on MPN pathogenesis, many questions remain to be answered to develop effective therapies to cure MPN or impair its progression to acute myeloid leukemia. The present study examined the expression levels of the Hippo signaling pathway members in patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), as well as the role that they play in disease pathogenesis. The Hippo pathway is a tumor suppressor pathway that participates in the regulation of cell proliferation, differentiation, and death. Our main finding was that the expression of tumor suppressor genes from Hippo pathway were downregulated and seemed to be associated with cell resistance to apoptosis and increased proliferation rate. Therefore, the decreased expression of Hippo pathway-related genes may contribute to the malignant phenotype, apoptosis resistance, and cell proliferation in MPN pathogenesis.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cacemiro</LastName>
            <ForeName>Maira da Costa</ForeName>
            <Initials>MDC</Initials>
            <Identifier Source="ORCID">0000-0002-4170-2063</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil. mairacacemiro@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cominal</LastName>
            <ForeName>Juçara Gastaldi</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pereira</LastName>
            <ForeName>Luiz Miguel</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berzoti-Coelho</LastName>
            <ForeName>Maria Gabriela</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berbel</LastName>
            <ForeName>Giovana Michelassi</ForeName>
            <Initials>GM</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baroni</LastName>
            <ForeName>Luciana</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malta</LastName>
            <ForeName>Tathiane</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tognon</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Federal University of Juiz de Fora, Campus Governador Valadares, Governador Valadares, MG, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nunes</LastName>
            <ForeName>Natalia de Souza</ForeName>
            <Initials>NS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Souto</LastName>
            <ForeName>Elizabeth Xisto</ForeName>
            <Initials>EX</Initials>
            <AffiliationInfo>
              <Affiliation>Euryclides de Jesus Zerbini Transplant Hospital, São Paulo, SP, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Figueiredo-Pontes</LastName>
            <ForeName>Lorena Lobo</ForeName>
            <Initials>LL</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yatsuda</LastName>
            <ForeName>Ana Patricia</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Castro</LastName>
            <ForeName>Fabíola Attié</ForeName>
            <Initials>FA</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil. castrofa@fcfrp.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Med Oncol</MedlineTA>
        <NlmUniqueID>9435512</NlmUniqueID>
        <ISSNLinking>1357-0560</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037282">Calreticulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053628">Receptors, Thrombopoietin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D037282" MajorTopicYN="N">Calreticulin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090683" MajorTopicYN="N">Hippo Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053614" MajorTopicYN="N">Janus Kinase 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009196" MajorTopicYN="Y">Myeloproliferative Disorders</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011087" MajorTopicYN="Y">Polycythemia Vera</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055728" MajorTopicYN="Y">Primary Myelofibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053628" MajorTopicYN="N">Receptors, Thrombopoietin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Cell proliferation</Keyword>
        <Keyword MajorTopicYN="N">Hippo signaling pathway</Keyword>
        <Keyword MajorTopicYN="N">LATS2</Keyword>
        <Keyword MajorTopicYN="N">Myeloproliferative neoplasms</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>23</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35599283</ArticleId>
        <ArticleId IdType="doi">10.1007/s12032-022-01696-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s12032-022-01696-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14820991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17210175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C. Diaconu C, Gurban P, Mambet C, Chivu-Economescu M, G. Necula L, Matei L, et al. Programmed Cell Death Deregulation in BCR-ABL1-Negative Myeloproliferative Neoplasms. In: Gali-Muhtasib H, Nasser Rahal O, editors. Programmed Cell Death. IntechOpen; 2020 [cited 2021 Mar 23]. Available from: https://www.intechopen.com/books/programmed-cell-death/programmed-cell-death-deregulation-in-bcr-abl1-negative-myeloproliferative-neoplasms</Citation>
        </Reference>
        <Reference>
          <Citation>Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, et al. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis. J Hematol Oncol. 2012;5:2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22300941</ArticleId>
            <ArticleId IdType="pmc">3298534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15793561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15837627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huijsmans CJJ, Poodt J, Savelkoul PHM, Hermans MHA. Sensitive detection and quantification of the JAK2V617F allele by real-time PCR. J Mol Diagn. 2011;13:558–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21723417</ArticleId>
            <ArticleId IdType="pmc">3157608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodama T, Hikita H, Kawaguchi T, Shigekawa M, Shimizu S, Hayashi Y, et al. Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ. 2012;19:1856–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22790873</ArticleId>
            <ArticleId IdType="pmc">3469054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16868251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plo I, Bellanné-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W. Genetic alterations of the thrombopoietin/MPL/JAK2 axis impacting megakaryopoiesis. Front Endocrinol (Lausanne). 2017;8:234.</Citation>
        </Reference>
        <Reference>
          <Citation>Chaligné R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22:1557–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18528423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki M, Komatsu N. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. Cancer Sci. 2017;108:1907–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28741795</ArticleId>
            <ArticleId IdType="pmc">5623763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R-I, Marty C, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26668133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salati S, Genovese E, Carretta C, Zini R, Bartalucci N, Prudente Z, et al. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Sci Rep. 2019;9:10558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31332222</ArticleId>
            <ArticleId IdType="pmc">6646313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Huang J, Dong J, Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003;114:445–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couzens AL, Knight JDR, Kean MJ, Teo G, Weiss A, Dunham WH, et al. Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci Signal. 2013;6:rs15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24255178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong W, Guan K-L. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23:785–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22659496</ArticleId>
            <ArticleId IdType="pmc">3459069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22:1962–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18579750</ArticleId>
            <ArticleId IdType="pmc">2492741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29426921</ArticleId>
            <ArticleId IdType="pmc">5807384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dijkstra-Tiekstra MJ, Setroikromo AC, Kraan M, Gkoumassi E, de Wildt-Eggen J. Is hydroxyethyl starch necessary for sedimentation of bone marrow? Transfus Apheres Sci. 2015;52:94–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Chicaybam L, Barcelos C, Peixoto B, Carneiro M, Limia CG, Redondo P, et al. An efficient electroporation protocol for the genetic modification of mammalian cells. Front Bioeng Biotechnol. 2017. https://doi.org/10.3389/fbioe.2016.00099/full .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fbioe.2016.00099/full</ArticleId>
            <ArticleId IdType="pubmed">28168187</ArticleId>
            <ArticleId IdType="pmc">5253374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo H, Hao R, Wei Y, Sun D, Sun S, Zhang Z. Optimization of electrotransfection conditions of mammalian cells with different biological features. J Membr Biol. 2012;245:789–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22836669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138:9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21138973</ArticleId>
            <ArticleId IdType="pmc">2998162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badouel C, Garg A, McNeill H. Herding Hippos: regulating growth in flies and man. Curr Opin Cell Biol. 2009;21:837–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19846288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosaka Y, Mimori K, Tanaka F, Inoue H, Watanabe M, Mori M. Clinical significance of the loss of MATS1 mRNA expression in colorectal cancer. Int J Oncol. 2007;31:333–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17611689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki H, Kawano O, Endo K, Suzuki E, Yukiue H, Kobayashi Y, et al. Human MOB1 expression in non-small-cell lung cancer. Clin Lung Cancer. 2007;8:273–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17311693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji T, Liu D, Shao W, Yang W, Wu H, Bian X. Decreased expression of LATS1 is correlated with the progression and prognosis of glioma. J Exp Clin Cancer Res. 2012;31:67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22909338</ArticleId>
            <ArticleId IdType="pmc">3561646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V, Franco R, et al. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer. 2011;47:926–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21131195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhyani A, Duarte ASS, Machado-Neto JA, Favaro P, Ortega MM, Olalla Saad ST. ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. FEBS Lett. 2012;586:4311–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23142581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116:953–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20421449</ArticleId>
            <ArticleId IdType="pmc">2924229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado-Neto JA, de Melo CP, Olalla Saad ST, Traina F. YAP1 expression in myelodysplastic syndromes and acute leukemias. Leuk Lymphoma. 2014;55:2413–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24605912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gholami M, Mirfakhraie R, Movafagh A, Jalaeekhoo H, Kalahroodi R, Zare-Abdollahi D, et al. The expression analysis of LATS2 gene in de novo AML patients. Med Oncol. 2014;31:961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24743869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers. Nat Med. 2014;20:599–606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24813251</ArticleId>
            <ArticleId IdType="pmc">4057660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jansson L, Larsson J. Normal hematopoietic stem cell function in mice with enforced expression of the hippo signaling effector YAP1. PLoS ONE. 2012;7:e32013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22363786</ArticleId>
            <ArticleId IdType="pmc">3283704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nehme NT, Schmid JP, Debeurme F, André-Schmutz I, Lim A, Nitschke P, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood. 2012;119:3458–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22174160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schäffer AA, et al. The phenotype of human STK4 deficiency. Blood. 2012;119:3450–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22294732</ArticleId>
            <ArticleId IdType="pmc">3325036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawahara M, Hori T, Chonabayashi K, Oka T, Sudol M, Uchiyama T. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood. 2008;112:3856–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18565851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa S, Yokoyama Y, Suzukawa K, Nanmoku T, Kurita N, Seki M, et al. Identification of a fusion gene composed of a Hippo pathway gene MST2 and a common translocation partner ETV6 in a recurrent translocation t(8;12)(q22;p13) in acute myeloid leukemia. Ann Hematol. 2015;94:1431–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25933678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoner SA, Yan M, Liu KTH, Arimoto K-I, Shima T, Wang H-Y, et al. Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation. Blood. 2019;134:1730–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31434702</ArticleId>
            <ArticleId IdType="pmc">6856986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S, Ravid K. Role of a serine/threonine kinase, Mst1, in megakaryocyte differentiation. J Cell Biochem. 2000;76:44–60.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakhinia E, Farahangpour M, Tholouli E, Liu Yin JA, Hoyland JA, Byers RJ. Comparison of gene-expression profiles in parallel bone marrow and peripheral blood samples in acute myeloid leukaemia by real-time polymerase chain reaction. J Clin Pathol. 2006;59:1059–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16644881</ArticleId>
            <ArticleId IdType="pmc">1861748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiestner A, Marti GE, Billings EM, Liu H, Lee E, White T, et al. Differential gene expression in CLL cells from bone marrow and peripheral blood suggests a role of bone marrow stroma in leukemic cell proliferation. Blood. 2005;106:708–708.</Citation>
        </Reference>
        <Reference>
          <Citation>Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24:1488–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28644436</ArticleId>
            <ArticleId IdType="pmc">5563998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T, et al. Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-xL. Exp Cell Res. 2004;298:329–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15265683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo C, Liang C, Yang J, Hu H, Fan B, Liu X. LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma. Oncol Rep. 2019. https://doi.org/10.3892/or.2019.7065 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2019.7065</ArticleId>
            <ArticleId IdType="pubmed">31894346</ArticleId>
            <ArticleId IdType="pmc">6908932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du L. Jak/Stat and Hippo Signaling Pathways Independently Regulate the Same Target Genes To Control Cell Proliferation [Internet]. Digital Repository at the University of Maryland; 2014 [cited 2021 Mar 26]. Available from: http://hdl.handle.net/1903/16257</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
